Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454781 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3264782 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL8812022 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL300482 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL2346412 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL17777817 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL7989762 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL8574154 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3955770 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL29858099 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | claimed |
| US-9617241-B2 | Intermediate compounds and process for the preparation of efinaconazole | MAPI PHARMA LTD. (IL) | 2017-04-11 | — | — | US | disclosed |
| US-7569699-B2 | Process for producing epoxytriazole derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080081915-A1 | Process For Producing Epoxytriazole Derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2008-04-03 | — | — | US | disclosed |
| EP-0889881-B1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | NAEJA PHARMACEUTICAL INC (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-6153616-A | Triazoles as therapeutic agents for fungal infections | SYNPHAR LABORATORIES, INC. (CA) | 2000-11-28 | — | — | US | disclosed |
| EP-0889881-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES INC. (CA) | 1999-01-13 | — | — | EP | disclosed |
| WO-1998031675-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES, INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| EP-0698606-B1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMA CO LTD (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5620994-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0728752-A1 | Triazole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0698606-A1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5405861-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0421210-A2 | Triazole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081915-A1 | Process For Producing Epoxytriazole Derivative | CYP2E1, CYP1A1, SULT1A1 | CYP3A4 13/4885CYP2C9 109/4885CYP2C19 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.